Vivolux

About Us

Vivolux AB was founded in 2006, based on substances developed in-house and in collaboration with a research group in Uppsala that has developed an advanced system for preclinical analysis of cancer drugs based on tests using fresh human cancer cells. Collaboration was later established with Stig Linder's research group at the Karolinska Institute. This collaboration has resulted in access to a further unique method for evaluating the effects of cancer drugs. In contrast to the standard method, which is used by leading pharmaceutical companies, three-dimensional aggregates of human cancer cells are used as models of solid tumors. This facilitates identification and optimization of drug candidates that can reach and kill all cells deep in the tumor tissue. With the aid of these unique methods, several drug candidates have been identified and optimized.

Quotes

The article in Blood is a mark of quality and a milestone for the researchers. There is a considerable medical need for new cancer drugs and the development that is taking place within the framework of Vivolux is very much leading edge, as shown by Harvard Medical School and other leading institutions

Hans Rosén, Vivolux Chief Executive

The published mechanism of action is extremely interesting in the creation of new cancer drugs. We feel very excited about exploring the therapeutic potential of this new drug candidate in clinical studies. Our hope is that our joint research will lead to improved cancer treatment.

Dr. Dharminder Chauhan, Harvard Medical School

Pick a time period -

Tags ( Active)

All Regulatory Non-Regulatory

FDA grants clearance to proceed with clinical study – new drug candidate from Vivolux could overcome drug resistance

Tue, Oct 07, 2014 14:00 CET

Vivolux, a pharmaceutical company specialized in cancer treatment, announced today that the FDA has granted clearance to proceed with VLX1570 to clinical phase I/II for treatment against relapsed and/or refractory multiple myeloma. Researchers at Vivolux have discovered a novel cancer drug target within the proteasome in tumor cells. This novel drug candidate inhibits tumor growth and prolongs survival in multiple myeloma in preclinical models that are resistant to conventional therapies.The clinical study will be conducted in collaboration with the Memorial Sloan-Kettering Cancer Center

There are no items matching the current filter

There are no more items matching the current filter

Share

About Us

Quotes

FDA grants clearance to proceed with clinical study – new drug candidate from Vivolux could overcome drug resistance